Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a “mutatomics” screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.
|Publication status||Published - 2005|
|MoE publication type||A1 Journal article-refereed|
- tumor suppressor gene
Wolf, M., Edgren, H., Muggerud, A., Kilpinen, S., Huusko, P., Sørlie, T., Mousses, S., & Kallioniemi, O. (2005). NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. Cellular Oncology, 27(3), 169-173. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617499/#